BioNTech has agreed to acquire all the shares of CureVac, a clinical-stage biotech company developing a novel class of transformative medicines in oncology and infectious diseases based on messenger ribonucleic acid (mRNA). The all-stock transaction will bring together two complementary companies based in Germany and will build on BioNTech’s proven track record and established position in the global mRNA industry. With the acquisition, BioNTech aims to strengthen the research, development,...